IMPINGEMENT SYNDROME MARKET ANALYSIS

Market News

Recent Developments

• Advanced surgical techniques: There have been advancements in surgical techniques for the treatment of impingement syndrome, including minimally invasive arthroscopic procedures. These techniques involve smaller incisions, reduced tissue trauma, and faster recovery times as compared to traditional open surgery.
• Regenerative medicine: The use of regenerative medicine approaches, such as platelet-rich plasma (PRP) injections or stem cell therapy, has been explored for the treatment of impingement syndrome. These therapies aim to promote tissue healing and regeneration.
• Rehabilitation Protocols: There have been developments in rehabilitation protocols and physical therapy techniques for individuals with impingement syndrome. These protocols focus on strengthening the shoulder muscles, improving range of motion, and thereby optimizing biomechanics to alleviate impingement symptoms.

Acquisition, Collaboration and Partnership

• In November 2022, Arthrex, one of the leader in multispecialty, minimally invasive surgical technology, medical research, manufacturing and medical education and Richard Wolf, a full-service provider in endoscopy, offering a wide range of instrumentation and system solutions for minimally invasive medicine announced a U.S.-based partnership to offer comprehensive technology and product offerings in urology, gynecology and general surgery.
• In August 2022, CONMED Corporation acquired Biorez, Inc. CONMED Corporation, a medical technology company that provides surgical devices and equipment for minimally invasive procedures announced a definitive agreement to Acquire Biorez, Inc., a U.S. based medical device start-up focused on advancing the healing of soft tissues using its proprietary BioBrace Implant technology.
• In July 2022, Bioventus Inc., one of the global leader of innovations for active healing and surgical orthobiologics announced that it has completed its acquisition of CartiHeal., a privately-held medical device company to add CartiHeal to our diverse portfolio of active healing solutions.
• In July 2021, Celularity Inc., a clinical-stage biotechnology company developing innovative cell therapies and biomaterial products and Arthrex, Inc., one of global leader in minimally invasive orthopedic technology announced that both the companies have entered into an exclusive partnership to distribute and commercialize CelularityInc.’s biomaterial products for orthopedic surgery and sports medicine.